Miracle Survivors

Langreth, Robert
March 2009
Forbes Asia;3/2/2009, Vol. 5 Issue 3, p30
The article focuses on miraculous recovery of patient Charles Burrows from liver cancer and the research on cancer therapy. Spontaneous tumor regressions are among the rarest and most mysterious events in medicine, with only several hundred cases in the literature that can be considered well documented. Big drug companies, including Pfizer, Bristol-Myers Squibb and Sanofi-Aventis, are doggedly pursuing drugs that aim to boost the immune system to fight cancer.


Related Articles

  • Pharma: Clinic Roundup.  // BioWorld Today;7/23/2012, Vol. 23 Issue 141, p6 

    The article reports on a statement by Bristol-Myers Squibb Co. of New York that its brivanib, a candidate for liver cancer, failed to meet its primary overall survival objective based on a noninferiority statistical design in a clinical trial.

  • Bristol-Myers' Immune-Drug Success in Cancer May Spur Industry Race.  // MondayMorning;6/11/2012, Vol. 20 Issue 23, p1 

    The article informs that success of an experimental drug from Bristol-Myers Squibb Co. to unleash the body's immune-system defenses against cancer has prompted industry wide race to produce similar treatments. According to data reported at the American Society of Clinical Oncology meeting on...

  • Bristol-Myers Squibb Co. (New York) is making progress developing a new drug to assist the body's immune system in its ability to find and attack cancer cells.  // MondayMorning;6/4/2012, Vol. 20 Issue 22, p1 

    The article informs that a new drug, known as BMS-936558, is being developed by Bristol-Myers Squibb Co. to assist the body's immune system in its ability to find and attack cancer cells. It has been informed that the company had received the approval in March 2011 to develop the drug. It has...

  • BRISK-FL Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Does Not Meet Overall Survival Primary Endpoint.  // Biomedical Market Newsletter;7/26/2012, Vol. 21, p1 

    The article informs that Bristol-Myers Squibb Co. has released the results from the clinical trial of brivanib and sorafenib for the treatment of hepatocellular carcinoma. It further informs that the company will be presenting the results at an upcoming scientific meeting. It mentions that...

  • Bristol-Myers Squibb Announces Global Collaboration with Leading Academic Institutions to Advance Science of Immuno-Oncology.  // Biomedical Market Newsletter;6/1/2012, Vol. 21, p1 

    The article offers information on the International Immuno Oncology Network which has been formed by global collaboration between Bristol-Myers Squibb Company and leading academic institutions. The Immuno oncology network aims to harness the immune system's intelligence of the body to fight...

  • Drug development: Try and try again. Scudellari, Megan // Nature;12/4/2014 Supplement, Vol. 516 Issue s7529, pS4 

    The article discuses challenges in drug development for liver cancer by the drug companies and highlights the success of various approaches. Clinical trials of pharmaceutical companies such as Eli Lilly, Bristol-Myers Squibb and Pfizer are discussed. Failure of drug trials in hepatocellular...

  • Clinic Roundup.  // BioWorld Today;5/7/2013, Vol. 24 Issue 87, p7 

    This section offers news briefs on clinical trials by biotechnology companies in the U.S. as of May 2013. Bristol-Myers Squibb Co. revealed results from a subgroup analysis of a research study of the drug metreleptin for metabolic disorders linked with lipodystrophy (LD). Isis Pharmaceuticals...

  • Taxol gets another nod from FDA.  // American Nurseryman;10/1/94, Vol. 180 Issue 7, p20 

    Reports that the New York City-based Bristol-Myers Squibb Co. has received clearance from the Food and Drug Administration for use of its cancer drug Taxol in breast cancer cases where initial chemotherapy fails. Previous approval of the drug for treatment of ovarian cases in cases where other...

  • Chiroscience and Bristol in cancer drug deal.  // Chemical Market Reporter;02/16/98, Vol. 253 Issue 7, p17 

    Focuses on the research and licensing agreement between Chiroscience Group PLC and Bristol-Myers Squibb Co. centered on the area of matrix metalloproteinase inhibitors for the treatment of cancer.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics